---
title: "Lakewood-Amedex Biotherapeutics Drops Over 3% Intraday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284029121.md"
description: "Lakewood - Amedisys (LABT.US) current price $8.34, down 3.58% for the day, with a rapid decline accelerating within 5 minutes. As a small-cap company in the biopharmaceutical sector, LABT has not disclosed any significant announcements recently. This rapid intraday drop may be related to fluctuations in short-term capital sentiment and weak liquidity. The market is paying attention to changes in trading volume and whether there will be any follow-up fundamental news"
datetime: "2026-04-24T15:29:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284029121.md)
  - [en](https://longbridge.com/en/news/284029121.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284029121.md)
---

# Lakewood-Amedex Biotherapeutics Drops Over 3% Intraday

Lakewood-Amedex Biotherapeutics (LABT.US) fell to $8.34, down **3.58%** intraday, with the decline accelerating within a 5-minute window.

The biopharmaceutical company has no recent material announcements on record; the intraday selloff appears driven by short-term sentiment and thin liquidity rather than fundamental catalysts, with market participants monitoring volume for signs of further pressure.

### Related Stocks

- [LABT.US](https://longbridge.com/en/quote/LABT.US.md)

## Related News & Research

- [Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push](https://longbridge.com/en/news/284022381.md)
- [Biopharmaceutical Company Teva to Bring Innovative Migraine Treatment to China With NeuroGen Pharma](https://longbridge.com/en/news/283652385.md)
- [NoviqTech Subsidiary Coralia Signs Large-Scale Carbon Removal Offtake Agreement with Pure Data Centres](https://longbridge.com/en/news/283425552.md)
- [Celularity Amends NexGel Biomaterials Sale to $13.3 Million With $8.3 Million Cash, $5 Million Note](https://longbridge.com/en/news/283508838.md)
- [Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative?](https://longbridge.com/en/news/283640022.md)